無料セミナー : 2019年11月19日『手術用ロボット:外科医療におけるトランスフォーメーション』 BIS Research共同開催

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

薬理ゲノム学 (ファーマコゲノミクス) の世界市場:分析と予測 (2019-2028年)

Global Pharmacogenomics Market: Focus on Services, Applications, Technologies, End Users, Country Data (16 Countries), and Competitive Landscape - Analysis and Forecast, 2019-2028

発行 BIS Research Inc. 商品コード 853986
出版日 ページ情報 英文 287 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.93円で換算しております。
Back to Top
薬理ゲノム学 (ファーマコゲノミクス) の世界市場:分析と予測 (2019-2028年) Global Pharmacogenomics Market: Focus on Services, Applications, Technologies, End Users, Country Data (16 Countries), and Competitive Landscape - Analysis and Forecast, 2019-2028
出版日: 2019年05月21日 ページ情報: 英文 287 Pages
概要

世界における薬理ゲノム学 (ファーマコゲノミクス) 市場は、2028年までに89億8,000万米ドルへ達すると予測されています。

当レポートでは、世界における薬理ゲノム学 (ファーマコゲノミクス) 市場を調査し、市場および製品の概要、市場成長への各種影響因子および市場機会の分析、各セグメント・主要国別の動向と市場規模の推移と予測、競合環境、主要企業のプロファイルなど、体系的な情報を提供しています。

第1章 市場概要

第2章 市場力学

  • 概要
  • 氷山分析:世界の薬理ゲノム学市場
  • 影響分析
  • 市場成長推進要因
  • 市場成長抑制要因
  • 成長機会

第3章 競合情勢

  • 主な戦略・発展
  • 市場シェア分析
  • 成長シェア分析
  • 産業の魅力

第4章 規制の枠組み

  • 米国における法的要件・枠組み
  • 欧州における法的要件・枠組み
  • アジア太平洋における法的要件・枠組み
  • 特許情勢

第5章 世界の薬理ゲノム学 (ファーマコゲノミクス) 市場:サービス別

  • 概要
  • 遺伝子型決定
  • SNP同定
  • 薬理遺伝学検査
  • その他のサービス

第6章 世界の薬理ゲノム学 (ファーマコゲノミクス) 市場:用途別

  • 概要
  • 感染症
  • 神経学/精神医学
  • 心血管
  • その他の用途

第7章 世界の薬理ゲノム学 (ファーマコゲノミクス) 市場:技術別

  • 概要
  • ポリメラーゼ連鎖反応 (PCR)
  • マイクロアレイ
  • シーケンシング
  • その他の技術

第8章 世界の薬理ゲノム学 (ファーマコゲノミクス) 市場:エンドユーザー別

  • 概要
  • 調査組織
  • 医薬品企業
  • 診断センター
  • その他のエンドユーザー

第9章 世界の薬理ゲノム学 (ファーマコゲノミクス) 市場:地域別

  • 概要
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • その他 (RoW)

第10章 企業プロファイル

  • 概要
  • Abbott Laboratories
  • Admera Health, LLC
  • Agena Biosciences, Inc.
  • Cancer Genetics, Inc.
  • Dynamic DNA Laboratories
  • F. Hoffmann-La Roche Ltd
  • geneOmbio Technologies Pvt Ltd.
  • Genomic Health, Inc.
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings
  • Myriad Genetics, Inc.
  • Pathway Genomics Corporation
  • QIAGEN N.V.
  • Quest Diagnostics Incorporated
  • Thermo Fisher Scientific Inc.
  • Transgenomic, Inc.
  • 23andMe, Inc.
  • OneOme, LLC
  • Astra Zeneca PLC

第11章 調査範囲・手法

図表

List of Tables

  • Table 2.1: Impact Analysis of Market Drivers
  • Table 2.2: Impact Analysis of Market Restraints
  • Table 2.3: Examples of Adverse Drug Reactions
  • Table 4.1: Classification rules of IVDs under the IVDR
  • Table 4.2: Registration Criteria for IVD Medical Devices as per the CFDA

List of Figures

  • Figure 1: Estimates for Global Healthcare Market, 2018 and 2020
  • Figure 2: Impact of Market Drivers and Market Restraints on the Global Pharmacogenomics Market
  • Figure 3: Global Pharmacogenomics Market Snapshot (in $Million)
  • Figure 4: Dominating Segments of the Global Pharmacogenomics Market, 2018 and 2028
  • Figure 5: Global Pharmacogenomics Market (by Service), 2018 and 2028
  • Figure 6: Global Pharmacogenomics Market (by Application), 2018 and 2028
  • Figure 7: Global Pharmacogenomics Market (by Technology), 2018 and 2028
  • Figure 8: Global Pharmacogenomics Market (by End User), 2018 and 2028
  • Figure 9: Global Pharmacogenomics Market (by Region), 2018 and 2028
  • Figure 1.1: Evolution of Pharmacogenomics
  • Figure 1.2: Classification of Pharmacogenomics
  • Figure 1.3: Global Pharmacogenomics (PGx) Market, 2018-2028
  • Figure 2.1: Iceberg Analysis - Global Pharmacogenomics Market
  • Figure 2.2: Number of Deaths by Top 18 Infectious Diseases, 2015
  • Figure 2.3: Number of Deaths (in Millions) by Different Forms of Cancer, 2018
  • Figure 2.4: Benefits of Multiplexing Reactions
  • Figure 3.1: Share of Key Developments and Strategies, January 2016 - April 2019
  • Figure 3.2: Product Launches Share (by Company), January 2016 - April 2019
  • Figure 3.3: Product Approvals Share (by Company), January 2016 - April 2019
  • Figure 3 4: Synergistic Activities Share (by Company), January 2016 - April 2019
  • Figure 3.5: Market Share Analysis for the Global Pharmacogenomics Market, 2017
  • Figure 3.6: Market Share Analysis for the Global Pharmacogenomics Market, 2018
  • Figure 3.7: Growth Share Matrix for Global Pharmacogenomics Market (by Companies), 2018
  • Figure 3.8: Overall Industry Attractiveness, 2018 and 2028
  • Figure 3.9: Overall Impact of Bargaining Power of Suppliers
  • Figure 3.10: Overall Impact of Bargaining Power of Buyers
  • Figure 3.11: Overall Impact of Threat of New Entrants
  • Figure 3.12: Overall Impact of Threat of Substitute Products
  • Figure 3.13: Overall Impact of Intensity of Competitive Rivalry
  • Figure 4.1: Components Considered for Clinical Evidence as per the IVDR
  • Figure 4.2: Process of Medical Device Designation by the MHLW and PMDA
  • Figure 4.3: Share of Patents (by Ownership), 2016-2019
  • Figure 5.1: Global Pharmacogenomics Market (by Service)
  • Figure 5.2: Global Pharmacogenomics Market (by Service), 2018 and 2028
  • Figure 5.3: Global Pharmacogenomics Market (by Genotyping Service), 2018-2028
  • Figure 5.4: Global Pharmacogenomics Market (by SNP Identification Service), 2018-2028
  • Figure 5.5: Global Pharmacogenomics Market (by Pharmacogenetic Testing Service), 2018-2028
  • Figure 5.6: Global Pharmacogenomics Market (by Other Testing Services), 2018-2028
  • Figure 6.1: Global Pharmacogenomics Market (by Application)
  • Figure 6.2: Global Pharmacogenomics Market (by Application), 2018 and 2028
  • Figure 6.3: Global Pharmacogenomics Market (by Oncology), 2018-2028
  • Figure 6.4: Global Pharmacogenomics Market (by Infectious Diseases), 2018-2028
  • Figure 6.5: Global Pharmacogenomics Market (by Neurology/Psychiatry), 2018-2028
  • Figure 6.6: Global Pharmacogenomics Market (by Cardiovascular), 2018-2028
  • Figure 6.7: Global Pharmacogenomics Market (by Other Applications), 2018-2028
  • Figure 7.1: Global Pharmacogenomics Market (by Technology)
  • Figure 7.2: Global Pharmacogenomics Market (by Technology), 2018 and 2028
  • Figure 7.3: Global Pharmacogenomics Market (by PCR), 2018-2028
  • Figure 7.4: Global Pharmacogenomics Market (by Microarray), 2018-2028
  • Figure 7.5: Evolution of Sequencing for Molecular Diagnostics
  • Figure 7.6: Global Pharmacogenomics Market (by Sequencing), 2018-2028
  • Figure 7.7: Global Pharmacogenomics Market (by Other Technologies), 2018-2028
  • Figure 8.1: Global Pharmacogenomics Market (by End User)
  • Figure 8.2: Global Pharmacogenomics Market (by End User), 2018 and 2028
  • Figure 8.3: Global Pharmacogenomics Market (by Research Organizations), 2018-2028
  • Figure 8.4: Research Organizations (by Service), Share 2018 and 2028
  • Figure 8.5: Global Pharmacogenomics Market (by Pharmaceutical Companies), 2018-2028
  • Figure 8.6: Pharmaceutical Companies (by Service), 2018 and 2028
  • Figure 8.7: Global Pharmacogenomics Market (by Diagnostic Centers), 2018-2028
  • Figure 8.8: Diagnostics Centers (by Service), 2018 and 2028
  • Figure 8.9: Global Pharmacogenomics Market (by Other End Users), 2018-2028
  • Figure 9.1: Global Pharmacogenomics Market (by Region), 2018 and 2028
  • Figure 9.2: Global Pharmacogenomics Market (by Region), 2018-2028
  • Figure 9.3: Global Pharmacogenomics Market Share (by Region), 2018
  • Figure 9.4: Global Pharmacogenomics Market Share (by Region), 2028
  • Figure 9.5: North America Pharmacogenomics Market, 2018-2028
  • Figure 9.6: North America: Market Dynamics
  • Figure 9.7: North America Pharmacogenomics Market (by Country), 2018-2028
  • Figure 9.8: The U.S. Pharmacogenomics Market, 2018-2028
  • Figure 9.9: Canada Pharmacogenomics Market, 2018-2028
  • Figure 9.10: North America Pharmacogenomics Market (by Application), 2018 and 2028
  • Figure 9.11: North America Pharmacogenomics Market (by Service), 2018 and 2028
  • Figure 9.12: Europe Pharmacogenomics Market, 2018-2028
  • Figure 9.13: Europe: Market Dynamics
  • Figure 9.14: Europe Pharmacogenomics Market (by Country), 2018-2028
  • Figure 9.15: Germany Pharmacogenomics Market, 2018-2028
  • Figure 9.16: The U.K. Pharmacogenomics Market, 2018-2028
  • Figure 9.17: France Pharmacogenomics Market, 2018-2028
  • Figure 9.18: Italy Pharmacogenomics Market, 2018-2028
  • Figure 9 19: Spain Pharmacogenomics Market, 2018-2028
  • Figure 9 20: Denmark Pharmacogenomics Market, 2018-2028
  • Figure 9.21: The Netherlands Pharmacogenomics Market, 2018-2028
  • Figure 9.22: Rest-of-Europe Pharmacogenomics Market, 2018-2028
  • Figure 9.23: Europe Pharmacogenomics Market (by Application), 2018 and 2028
  • Figure 9.24: Europe Pharmacogenomics Market (by Service), 2018 and 2028
  • Figure 9.25: Asia-Pacific Pharmacogenomics Market, 2018-2028
  • Figure 9.26: APAC: Market Dynamics
  • Figure 9.27: APAC Pharmacogenomics Market (by Country), 2018-2028
  • Figure 9.28: Japan Pharmacogenomics Market, 2018-2028
  • Figure 9.29: China Pharmacogenomics Market, 2018-2028
  • Figure 9.30: Australia Pharmacogenomics Market, 2018-2028
  • Figure 9.31: India Pharmacogenomics Market, 2018-2028
  • Figure 9.32: Singapore Pharmacogenomics Market, 2018-2028
  • Figure 9.33: RoAPAC Pharmacogenomics Market, 2018-2028
  • Figure 9.34: Asia-Pacific Pharmacogenomics Market (by Application), 2018 and 2028
  • Figure 9.35: Asia-Pacific Pharmacogenomics Market (by Service), 2018 and 2028
  • Figure 9.36: Latin America Pharmacogenomics Market, 2018-2028
  • Figure 9.37: Latin America: Market Dynamics
  • Figure 9.38: Latin America Pharmacogenomics Market (by Country), 2018-2028
  • Figure 9.39: Brazil Pharmacogenomics Market, 2018-2028
  • Figure 9.40: Mexico Pharmacogenomics Market, 2018-2028
  • Figure 9.41: Rest-of-Latin America Pharmacogenomics Market, 2018-2028
  • Figure 9.42: Latin America Pharmacogenomics Market (by Application), 2018 and 2028
  • Figure 9.43: Latin America Pharmacogenomics Market (by Service), 2018 and 2028
  • Figure 9.44: RoW Pharmacogenomics Market, 2018-2028
  • Figure 9.45: RoW Pharmacogenomics Market (by Application), 2018 and 2028
  • Figure 9.46: RoW Pharmacogenomics Market (by Service), 2018 and 2028
  • Figure 10.1: Total Number of Companies Profiled
  • Figure 10.2: Abbott Laboratories: Overall Product Portfolio
  • Figure 10.3: Abbott Laboratories: Overall Financials, 2016-2018
  • Figure 10.4: Abbott Laboratories: Revenue (by Segment), 2016-2018
  • Figure 10.5: Abbott Laboratories: Revenue Split for Diagnostics, 2016-2018
  • Figure 10.6: Abbott Laboratories: Revenue (by Region), 2016-2018
  • Figure 10.7: Abbott Laboratories: R&D Expenditure, 2016-2018
  • Figure 10.8: Abbott Laboratories: SWOT Analysis
  • Figure 10.9: Admera Health, LLC: Overall Product Portfolio
  • Figure 10.10: Admera Health, LLC: SWOT Analysis
  • Figure 10.11: Agena Biosciences, Inc.: Overall Product Portfolio
  • Figure 10.12: Agena Biosciences, Inc.: SWOT Analysis
  • Figure 10.13: Product Portfolio: Cancer Genetics, Inc.
  • Figure 10.14: Cancer Genetics, Inc.: Overall Financials, 2016-2018
  • Figure 10.15: Cancer Genetics, Inc.: Revenue (by Segment), 2016-2018
  • Figure 10.16: Cancer Genetics, Inc.: R&D Expenditure, 2016-2018
  • Figure 10.17: Cancer Genetics, Inc.: SWOT Analysis
  • Figure 10.18: Dynamic DNA Laboratories: Overall Product Portfolio
  • Figure 10.19: Dynamic DNA Laboratories: SWOT Analysis
  • Figure 10.20: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
  • Figure 10.21: F. Hoffmann-La Roche Ltd: Overall Financials, 2016-2018
  • Figure 10.22: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2016-2018
  • Figure 10.23: F. Hoffmann-La Roche Ltd: Revenue Split for Diagnostics, 2016-2018
  • Figure 10.24: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2016-2018
  • Figure 10.25: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2016-2018
  • Figure 10.26: F. Hoffmann-La Roche Ltd: SWOT Analysis
  • Figure 10.27: geneOmbio Technologies Pvt Ltd.: Overall Product Portfolio
  • Figure 10.28: geneOmbio Technologies Pvt Ltd.: SWOT Analysis
  • Figure 10.29: Genomic Health, Inc.: Overall Product Portfolio
  • Figure 10.30: Genomic Health, Inc.: Overall Financials, 2016-2018
  • Figure 10.31: Genomic Health, Inc.: Revenue (by Segment), 2016-2018
  • Figure 10.32: Genomic Health, Inc.: Revenue (by Region), 2016-2018
  • Figure 10.33: Genomic Health, Inc.: R&D Expenditure, 2016-2018
  • Figure 10.34: Genomic Health, Inc.: SWOT Analysis
  • Figure 10.35: Illumina, Inc.: Overall Product Portfolio
  • Figure 10.36: Illumina, Inc.: Overall Financials, 2016-2018
  • Figure 10.37: Illumina, Inc.: Revenue (by Segment), 2016-2018
  • Figure 10.38: Illumina, Inc.: Revenue (by Region), 2016-2018
  • Figure 10.39: Illumina, Inc.: R&D Expenditure, 2016-2018
  • Figure 10.40: Illumina, Inc.: SWOT Analysis
  • Figure 10.41: Laboratory Corporation of America Holdings: Overall Product Portfolio
  • Figure 10.42: Laboratory Corporation of America Holdings: Overall Financials, 2016-2018
  • Figure 10.43: Laboratory Corporation of America Holdings: Revenue (by Segment), 2016-2018
  • Figure 10.44: Laboratory Corporation of America Holdings: Revenue (by Region), 2018
  • Figure 10.45: Laboratory Corporation of America Holdings: SWOT Analysis
  • Figure 10.46: Myriad Genetics, Inc.: Overall Product Portfolio
  • Figure 10.47: Myriad Genetics, Inc.: Overall Financials, 2016-2018
  • Figure 10.48: Myriad Genetics, Inc.: Revenue (by Business Segment), 2016-2018
  • Figure 10.49: Myriad Genetics, Inc.: SWOT Analysis
  • Figure 10.50: Pathway Genomics Corporation: Overall Product Portfolio
  • Figure 10.51: Pathway Genomics Corporation: SWOT Analysis
  • Figure 10.52: QIAGEN N.V.: Overall Product Portfolio
  • Figure 10.53: QIAGEN N.V.: Overall Financials, 2016-2018
  • Figure 10.54: QIAGEN N.V.: Revenue (by Segment), 2016-2018
  • Figure 10.55: QIAGEN N.V.: Revenue (by Region), 2016-2018
  • Figure 10.56: QIAGEN N.V.: R&D Expenditure, 2016-2018
  • Figure 10.57: QIAGEN N.V.: SWOT Analysis
  • Figure 10.58: Product Portfolio: Quest Diagnostics Incorporated
  • Figure 10.59: Quest Diagnostics Incorporated: Overall Financials, 2016-2018
  • Figure 10.60: Quest Diagnostics Incorporated: Revenue (by Segment), 2016-2018
  • Figure 10.61: Quest Diagnostics Incorporated: SWOT Analysis
  • Figure 10.62: Thermo Fisher Scientific Inc.: Overall Product Portfolio
  • Figure 10.63: Thermo Fisher Scientific Inc.: Overall Financials, 2016-2018
  • Figure 10.64: Thermo Fisher Scientific Inc.: Revenue (by Segment), 2016-2018
  • Figure 10.65: Thermo Fisher Scientific Inc.: Revenue (by Region), 2016-2018
  • Figure 10.66: Thermo Fisher Scientific Inc.: R&D Expenditure, 2016-2018
  • Figure 10.67: Thermo Fisher Scientific Inc.: SWOT Analysis
  • Figure 10.68: Transgenomic, Inc.: Overall Product Portfolio
  • Figure 10.69: Transgenomic, Inc.: SWOT Analysis
  • Figure 10.70: 23and Me, Inc.: Overall Product Portfolio
  • Figure 10.71: OneOme, LLC: Overall Product Portfolio
  • Figure 11.1: Global Pharmacogenomics Market Segmentation
  • Figure 11.2: Global Pharmacogenomics Market Research Methodology
  • Figure 11.3: Primary Research
  • Figure 11.4: Secondary Research
  • Figure 11.5: Data Triangulation
  • Figure 11.6: Bottom-up Approach (Segment-wise Analysis)
  • Figure 11.7: Top-down Approach (Segment-wise Analysis)
  • Figure 11.8: Assumptions and Limitations
  • Figure 11.9: Considered Factors for Data Prediction and Modeling
目次
Product Code: BH007B

Global Pharmacogenomics Market to Reach $8.98 Billion by 2028

Pharmacogenomic services have significantly transformed the entire medical industry. With evolution of these services into direct-to-consumer tests, the global scope has been expanded to cover the entire healthcare gamut, further personalizing treatment modules. The rapid growth of clinically relevant pharmacogenomic knowledge and drugs used for patient treatment in virtually every medical specialty, is consistently aiding in the evolution of prevention-based treatment. With a critical role in the global precision medicine phenomenon, pharmacogenomics is responsible for ensuring safe and effective application of targeted therapeutics. These individualized care regimes are improving the quality of life of the patients and reducing economic, societal, and clinical burden, projecting a future of prosperity.

Presently, service categories within the pharmacogenomics market include genotyping, SNP identification, and pharmacogenetic testing, among others. Although services are widespread, there is still considerable apprehension toward the adoption of genetic testing services in order to stratify patients for drug selection and dosage. Minimal reimbursement in developed countries such as the U.S., though restraining growth in the market, is being overcome by an increasing patient awareness that is leading to growth in the market.

The purpose of the study is to gain a holistic view of the global pharmacogenomics market in terms of various factors influencing it, including regulatory reforms, and technological advancements. The market has been segmented into 'services', 'applications', 'technologies', 'end users', and 'regions'. The scope of this report is centered upon conducting a detailed study of the products and services allied with the pharmacogenomics market. In addition, the study also includes the exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, growth potential of each service, application, technology, end user, region, and company, as well as other vital information with respect to global pharmacogenomics market. The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market.

This research report aims at answering various aspects of the global pharmacogenomics market with the help of the key factors driving the market, the restraints, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The report includes an in-depth examination of the key players and recent developments taking place in this market. Moreover, the report includes chapters on market dynamics (market drivers, opportunities, and challenges) and industry analysis as well.

The research study highlights the factors governing the industry attractiveness with Porter's Five Forces for a comprehensive understanding of the global pharmacogenomics market. Moreover, the study includes detailed product mapping, market estimation, and analysis of key trends in multiple geographical regions, growth of pharmacogenomics market in each region for different applications, and the key strategies and developments by the prominent pharmacogenomics manufacturers and service providers.

The answers to the following key questions can be derived from this report:

  • What are the major market drivers, challenges, and opportunities in the global pharmacogenomics market?
  • What are the underlying structures resulting in the emerging trends within the global pharmacogenomics market?
  • How will each segment of the global pharmacogenomics market grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2028?
  • What are the key developmental strategies which are implemented by the major players in order to sustain in the competitive market? What are the key regulatory implications in developed and developing regions for pharmacogenomics?
  • Who are the leading players with significant offerings to the global pharmacogenomics market? What is the current market dominance for each of these leading players?
  • What would be the compound growth rate witnessed by the leading players in the market during the forecast period 2019-2028? Which pharmacogenomics service type is estimated to witness the most promising growth?
  • What are the key applications in global pharmacogenomics market? What are the major segments of these applications?
  • What are the major technologies that are employed in the global pharmacogenomics market? Which is the dominating technology?
  • Who are the primary end users of the global pharmacogenomics market? Which is the fastest growing end use segment in the global pharmacogenomics market? What are the services that are being provided by these end users?
  • Who are the key manufacturers and service providers in the global pharmacogenomics market, and what are their contributions? Also, what is the growth potential of each major pharmacogenomics manufacturer and service provider?
  • What is the scope of the global pharmacogenomics market in North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World? Which pharmacogenomics application and service type dominate these regions?

Key trends targeted in the report:

  • What are the emerging trends in the global pharmacogenomics market? How are these trends revolutionizing the treatment procedure?
  • Which technologies are anticipated to break-through the current pharmacogenomics regime?
  • Which companies are anticipated to be highly disruptive in the future and why?
  • What are the regulatory procedures that are required to unify the approval process for emerging pharmacogenomics? How will these enhance the reimbursement scenario?
  • What are the gaps in regularizing optimum pharmacogenomics adoption in regular healthcare routines? How are these gaps being tackled?

The key manufacturers who have been contributing significantly to the global pharmacogenomics market include Abbott Laboratories, F. Hoffmann-La Roche Ltd, Illumina, Inc., Laboratory Corporation of America Holdings, Quest Diagnostics, Incorporated, Myriad Genetics, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., and Genomic Health, Inc., among others.

Executive Summary

As World Health Organization states, the global healthcare expenditure is on the course to be an exorbitant $8.5 trillion in 2020, owing to an increasing economic burden of chronic diseases, which are estimated to constitute almost 43% of the global economic burden. Thus, the escalating demand for better treatment outcome is leading to an ascending need for preventive, precise healthcare, and tailored medication. The growth of the precision medicine market over the last few years (2010-2017) has been colossal and has significantly contributed to giving rise to a number of parallel fields of study and possible healthcare implementations. Pharmacogenomics is defined as the study of the whole genome with respect to drug response, is consistently revolutionizing healthcare at the interface of precision medicine, with implications for drug development in order to provide superior treatment.

The rapid growth of clinically relevant pharmacogenomic knowledge and drugs used for patient treatment in virtually every medical specialty, is consistently aiding in the evolution of prevention-based treatment. With a critical role in the global precision medicine phenomenon, pharmacogenomics is responsible for ensuring safe and effective application of targeted therapeutics. The services offered by the major players in the pharmacogenomics market encompass categories such as genotyping, single nucleotide polymorphism (SNP) identification, and pharmacogenetic testing, among others. Also, several diagnostics and pharmaceutical companies are presently undertaking synergistic activities for the development of NGS-, PCR-, IHC-, ISH-, microarray-, or mass spectrometry-based pharmacogenomics for the applications in several disease indications, in order to enable efficient diagnosis, treatment selection, dosage selection, and treatment monitoring. The applications of pharmacogenomics primarily include oncology, infectious diseases, neurology/psychiatry, and cardiovascular, among others. Aside from the discovery of effective biomarkers for the development of efficient pharmacogenomics kits, obtaining regulatory approval is essential. The efficiency and effectiveness primarily depend upon the approval of a pharmacogenomics in the stratification of the patient population as responders and non-responders to aid in the selection of appropriate treatment. Therefore, the entire regulatory and approval process necessitates close collaboration between the manufacturer of the targeted drug and the manufacturer of corresponding genetic test. Besides research organizations, pharmaceutical companies, and diagnostic centers, among others, are also prominent end users of pharmacogenomics.

This growth has been primarily attributed to the major drivers in this market such as a highly increasing prevalence of infectious diseases and various types of cancer globally, increase in adoption of personalized medicine shifting the paradigm from reaction to prevention on a global level, increasing rate of adverse drug reaction, and surge in usage of pharmacogenomics for drug discovery and development. These individualized care regimes are improving quality of life of the patients and reducing economic, societal, and clinical burden, projecting a future of prosperity.

Presently, service categories within the pharmacogenomics market include genotyping, SNP identification, and pharmacogenetic testing. Till date, the healthcare industry has witnessed a number of successful products and services that have contributed significantly to the enhancement of technological advancements in making treatment more precise. As of 2018, pharmacogenomics, though minimally reimbursed, can be seen to have large-scale exposure in almost all the developed countries. However, with the rapid advancements taking place and an exponential progression in the number of companies entering the space, access to consumers is bound to become easier, thus significantly increasing the exposure in less-developed countries. The global pharmacogenomics market has been witnessing a steady growth since the end of the Human Genome Project in 2003. The market is expected to continue to grow with a double digit CAGR of 6.98% during the forecast period, 2019-2028. Growing at a CAGR of 6.42% during the forecast period of 2019-2028, the genotyping service segment is anticipated to generate a value of $3.54 billion in 2028. However, the global market for pharmacogenetic testing services is anticipated to grow at the fastest CAGR of 8.95% during the forecast period 2019-2028.

The purpose of the study is to gain a holistic view of the global pharmacogenomics market in terms of various factors influencing the same, including regulatory reforms, and technological advancements. The market has been segmented into 'services', 'applications', 'technologies', 'end users', and 'regions'. The scope of this report is centered upon conducting a detailed study of the products and services allied with the pharmacogenomics market. In addition, the study also includes the exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, growth potential of each service, application, technology, end user, region, and company, as well as other vital information with respect to global pharmacogenomics market.

Based on the region, the global pharmacogenomics market is segmented into North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World (RoW). North America is the leading contributor to the global pharmacogenomics market and was responsible for a 50.89% share of the global market values in 2018. However, the Asia-Pacific region is expected to grow at the fastest pace among all other regions with a CAGR of 8.82% during the forecast period 2019-2028.

The key players who have been contributing significantly to the global pharmacogenomics market include Abbott Laboratories, F. Hoffmann-La Roche Ltd, Illumina, Inc., Laboratory Corporation of America Holdings, Quest Diagnostics, Incorporated, Myriad Genetics, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., and Genomic Health, Inc., among others.

Table of Contents

  • 1 Market Overview
  • 1.1 Introduction
  • 1.2 Market Definition
  • 1.3 Historical Perspective
  • 1.4 Significant Services in Pharmacogenomics
  • 1.5 Classification of Pharmacogenomics
  • 1.6 Global Footprint
  • 1.7 Future Potential

2 Market Dynamics

  • 2.1 Overview
  • 2.2 Iceberg Analysis - Global Pharmacogenomics Market
  • 2.3 Impact Analysis
  • 2.4 Market Drivers
    • 2.4.1 Increasing Prevalence of Infectious Diseases and Various Types of Cancer, Globally
    • 2.4.2 Increase in Adoption of Personalized Medicine Shifting the Paradigm From Reaction to Prevention on a Global Level
    • 2.4.3 Increasing Rate of Adverse Drug Reaction
    • 2.4.4 Surge in Usage of Pharmacogenomics for Drug Discovery and Development
  • 2.5 Market Restraints
    • 2.5.1 Lack of Use of Available Data for Drug Development Initiatives
    • 2.5.2 Lack of High Complexity Testing Centers
    • 2.5.3 Difficulties in Detecting Gene Variation Affecting Drug Response
  • 2.6 Market Opportunities
    • 2.6.1 Massive Scope for Adoption of Pharmacogenomics in Emerging Nations
    • 2.6.2 Technological Advancements in Molecular Techniques for Pharmacogenomic Diagnostic Tests
    • 2.6.3 Rise of Direct-to-Consumer (DTC) Testing Services

3 Competitive Landscape

  • 3.1 Key Strategies and Developments
    • 3.1.1 Product Launches and Enhancements
    • 3.1.2 Product Approvals
    • 3.1.3 Synergistic Activities
    • 3.1.4 Mergers and Acquisitions
    • 3.1.5 Business Expansion Activities and Others
  • 3.2 Market Share Analysis
  • 3.3 Growth Share Analysis
  • 3.4 Industry Attractiveness
    • 3.4.1 Bargaining Power of Suppliers
    • 3.4.2 Bargaining Power of Buyers
    • 3.4.3 Threat of New Entrants
    • 3.4.4 Threat of Substitute Products
    • 3.4.5 Intensity of Competitive Rivalry

4 Regulatory Framework

  • 4.1 Legal Requirements and Framework in the U.S.
  • 4.2 Legal Requirements and Framework in Europe
  • 4.3 Legal Requirements and Framework in Asia-Pacific
    • 4.3.1 China
    • 4.3.2 Japan
  • 4.4 Patent Landscape

5 Global Pharmacogenomics Market (by Service)

  • 5.1 Overview
  • 5.2 Genotyping
  • 5.3 SNP Identification
  • 5.4 Pharmacogenetic Testing
  • 5.5 Other Services

6 Global Pharmacogenomics Market (by Application)

  • 6.1 Overview
  • 6.2 Oncology
  • 6.3 Infectious Diseases
  • 6.4 Neurology/Psychiatry
  • 6.5 Cardiovascular
  • 6.6 Other Applications

7 Global Pharmacogenomics Market (by Technology)

  • 7.1 Overview
  • 7.2 Polymerase Chain Reaction (PCR)
  • 7.3 Microarray
  • 7.4 Sequencing
  • 7.5 Other Technologies

8 Global Pharmacogenomics Market (by End User)

  • 8.1 Overview
  • 8.2 Research Organizations
    • 8.2.1 Research Organizations (by Service)
  • 8.3 Pharmaceutical Companies
    • 8.3.1 Pharmaceutical Companies (by Service)
  • 8.4 Diagnostic Centers
    • 8.4.1 Diagnostics Centers (by Service)
  • 8.5 Other End Users

9 Global Pharmacogenomics Market (by Region)

  • 9.1 Overview
  • 9.2 North America
    • 9.2.1 The U.S.
    • 9.2.2 Canada
    • 9.2.3 North America Pharmacogenomics Market (by Application)
    • 9.2.4 North America Pharmacogenomics Market (by Service)
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 The U.K.
    • 9.3.3 France
    • 9.3.4 Italy
    • 9.3.5 Spain
    • 9.3.6 Denmark
    • 9.3.7 The Netherlands
    • 9.3.8 Rest-of-Europe
    • 9.3.9 Europe Pharmacogenomics Market (by Application)
    • 9.3.10 Europe Pharmacogenomics Market (by Service)
  • 9.4 Asia-Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 Australia
    • 9.4.4 India
    • 9.4.5 Singapore
    • 9.4.6 Rest-of-APAC
    • 9.4.7 Asia-Pacific Pharmacogenomics Market (by Application)
    • 9.4.8 Asia-Pacific Pharmacogenomics Market (by Service)
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Rest-of-Latin America
    • 9.5.4 Latin America Pharmacogenomics Market (by Application)
    • 9.5.5 Latin America Pharmacogenomics Market (by Service)
  • 9.6 Rest-of-the-World
    • 9.6.1 RoW Pharmacogenomics Market (by Application)
    • 9.6.2 RoW Pharmacogenomics Market (by Service)

10 Company Profiles

  • 10.1 Overview
  • 10.2 Abbott Laboratories
    • 10.2.1 Company Overview
    • 10.2.2 Role of Abbott Laboratories in the Global Pharmacogenomics Market
    • 10.2.3 Financials
    • 10.2.4 Key Insights about Financial Health of the Company
    • 10.2.5 SWOT Analysis
  • 10.3 Admera Health, LLC
    • 10.3.1 Company Overview
    • 10.3.2 Role of Admera Health, LLC in the Global Pharmacogenomics Market
    • 10.3.3 SWOT Analysis
  • 10.4 Agena Biosciences, Inc.
    • 10.4.1 Company Overview
    • 10.4.2 Role of Agena Biosciences, Inc. in the Global Pharmacogenomics Market
    • 10.4.3 SWOT Analysis
  • 10.5 Cancer Genetics, Inc.
    • 10.5.1 Company Overview
    • 10.5.2 Role of Cancer Genetics, Inc. in the Global Pharmacogenomics Market
    • 10.5.3 Financials
    • 10.5.4 Key Insights about Financial Health of the Company
    • 10.5.5 SWOT Analysis
  • 10.6 Dynamic DNA Laboratories
    • 10.6.1 Company Overview
    • 10.6.2 Role of Dynamic DNA Laboratories in the Global Pharmacogenomics Market
    • 10.6.3 SWOT Analysis
  • 10.7 F. Hoffmann-La Roche Ltd
    • 10.7.1 Company Overview
    • 10.7.2 Role of F. Hoffmann-La Roche Ltd in the Global Pharmacogenomics Market
    • 10.7.3 Financials
    • 10.7.4 Key Insights about Financial Health of the Company
    • 10.7.5 SWOT Analysis
  • 10.8 geneOmbio Technologies Pvt Ltd.
    • 10.8.1 Company Overview
    • 10.8.2 Role of geneOmbio Technologies Pvt Ltd. In the Global Pharmacogenomics Market
    • 10.8.3 SWOT Analysis
  • 10.9 Genomic Health, Inc.
    • 10.9.1 Company Overview
    • 10.9.2 Role of Genomic Health, Inc. in the Global Pharmacogenomics Market
    • 10.9.3 Financials
    • 10.9.4 Key Insights about Financial Health of the Company
    • 10.9.5 SWOT Analysis
  • 10.10 Illumina, Inc.
    • 10.10.1 Company Overview
    • 10.10.2 Role of Illumina, Inc. in the Global Pharmacogenomics Market
    • 10.10.3 Financials
    • 10.10.4 Key Insights about Financial Health of the Company
    • 10.10.5 SWOT Analysis
  • 10.11 Laboratory Corporation of America Holdings
    • 10.11.1 Company Overview
    • 10.11.2 Role of Laboratory Corporation of America Holdings in the Global Pharmacogenomics Market
    • 10.11.3 Financials
    • 10.11.4 SWOT Analysis
  • 10.12 Myriad Genetics, Inc.
    • 10.12.1 Company Overview
    • 10.12.2 Role of Myriad Genetics, Inc. in the Global Pharmacogenomics Market
    • 10.12.3 Financials
    • 10.12.4 SWOT Analysis
  • 10.13 Pathway Genomics Corporation
    • 10.13.1 Company Overview
    • 10.13.2 Role of Pathway Genomics Corporation in the Global Pharmacogenomics Market
    • 10.13.3 SWOT Analysis
  • 10.14 QIAGEN N.V.
    • 10.14.1 Company Overview
    • 10.14.2 Role of QIAGEN N.V. in the Global Pharmacogenomics Market
    • 10.14.3 Financials
    • 10.14.4 Key Insights about Financial Health of the Company
    • 10.14.5 SWOT Analysis
  • 10.15 Quest Diagnostics Incorporated
    • 10.15.1 Company Overview
    • 10.15.2 Role of Quest Diagnostics Incorporated in the Global Pharmacogenomics Market
    • 10.15.3 Financials
    • 10.15.4 SWOT Analysis
  • 10.16 Thermo Fisher Scientific Inc.
    • 10.16.1 Company Overview
    • 10.16.2 Role of Thermo Fisher Scientific Inc. in the Global Pharmacogenomics Market
    • 10.16.3 Financials
    • 10.16.4 Key Insights about Financial Health of the Company
    • 10.16.5 SWOT Analysis
  • 10.17 Transgenomic, Inc.
    • 10.17.1 Company Overview
    • 10.17.2 Role of Transgenomic, Inc. in the Global Pharmacogenomics Market
    • 10.17.3 SWOT Analysis
  • 10.18 23andMe, Inc.
    • 10.18.1 Company Overview
    • 10.18.2 Role of 23andMe, Inc. in the Global Pharmacogenomics Market
  • 10.19 OneOme, LLC
    • 10.19.1 Company Overview
    • 10.19.2 Role of OneOme, LLC in the Global Pharmacogenomics Market
  • 10.20 Astra Zeneca PLC
    • 10.20.1 Company Overview
    • 10.20.2 Role of Astra Zeneca PLC in the Global Pharmacogenomics Market

11 Research Scope and Methodology

  • 11.1 Research Scope
  • 11.2 Global Pharmacogenomics Market: Research Methodology
Back to Top